Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter

Journal of the American College of Cardiology

Volumn 44, Issue 1, 2004, Pages 99-104

  Hohnloser, Stefan H ^a   Dorian, Paul ^b   Straub, Matthias ^c   Beckmann, Katrin ^c   Kowey, Peter ^d  

^a GOETHE UNIVERSITY   (Germany)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c Solvay Pharmaceuticals GmbH   (Germany)

^d Main Line Health Heart Center   (United States)

Author keywords

AF; AFL; atrial fibrillation; atrial flutter; ECG; electrocardiogram electrocardiographic; normal sinus rhythm; NSR

Indexed keywords

ANTIARRHYTHMIC AGENT; PLACEBO; TEDISAMIL;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BODY WEIGHT; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; RR INTERVAL PROLONGATION; SIDE EFFECT; SINUS RHYTHM; STAGING; SYMPTOMATOLOGY; TIME; TORSADE DES POINTES;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BICYCLO COMPOUNDS, HETEROCYCLIC; COMBINED MODALITY THERAPY; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 3242751339     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.03.047     Document Type: Article

References (19)

1. Go A.S., Hylek E.M., Philipps K.A., et al. Prevalence of diagnosed atrial fibrillation in adults National implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA. 285:2001;2370-2375
2. Feinberg W.M., Blackshear J.L., Laupacis A., et al. Prevalence, age distribution, and gender of patients with atrial fibrillation Analysis and implications. Arch Intern Med. 155:1995;469-473
3. Fuster V., Rydén L., Asinger R.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation Executive summary. Circulation. 104:2001;2118-2150
4. Wettwer E., Himmel H.M., Amos G.J., Li Q., Metzger F., Ravens U. Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br J Pharmacol. 125:1998;659-666
5. Nemeth M., Varro A., Thormählen D., Papp J. Tedisamil is a potent blocker of ATP-sensitive potassium channels in cardiac muscle. Exp Clin Cardiol. 2:1997;37-40
6. + channels. Cardiovasc Drugs Ther. 6:1992;321-327
7. Ravens U., Amos G.J., Li Q., Metzger F. Effects of the antiarrhythmic agent tedisamil. Exp Clin Cardiol. 2:1997;231-236
8. Baskin E.P., Lynch J.J. Differential atrial versus ventricular activities of class III potassium channel blockers. J Pharmacol Exp Ther. 285:1998;135-142
9. Opie LH. Tedisamil in coronary disease: additional benefits in the therapy of atrial fibrillation? J Cardiovasc Pharmacol Ther 2003; Suppl 1:S33-7.
10. Donovan K.D., Power B.M., Hockings B.E., Dobb G.J., Lee K.Y. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol. 75:1995;693-697
11. Boriani G., Biffi M., Capucci A., et al. Conversion of recent-onset atrial fibrillation to sinus rhythm Effects of different drug protocols. Pacing Clin Electrophysiol. 21:1998;2470-2474
12. Martinez-Marcoos F.J., Garcia-Garmendia J.L., Ortega-Carpio A., Fernandez-Gomes J.M., Santos J.M., Camacho C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol. 86:2000;950-953
13. Chevalier P., Durand-Dubief A., Burri H., Cucherat M., Kirkorian G., Touboul P. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation A meta-analysis. J Am Coll Cardiol. 41:2003;255-262
14. Hohnloser S.H., Singh B. Proarrhythmia with class III antiarrhythmic drugs Definition, electrophysiological mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol. 6:1995;920-936
15. Murray K.T. Ibutilide. Circulation. 97:1998;493-497
16. Ellenbogen K.A., Stambler B.S., Wood M.A., et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and flutter A dose-response study. J Am Coll Cardiol. 28:1996;130-136
17. Stambler B.S., Woods M.A., Ellenbogen K.A., et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 94:1996;1613-1621
18. Volgman A.S., Carberry P.A., Stambler B., et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 31:1998;1414-1419
19. Vanderlugt J.T., Mattioni T., Denker S., et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation. 100:1999;369-375